Lung Cancer Clinical Trial
Official title:
Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Flexible 19G Endobronchial Ultrasound Transbronchial Needle (Flex 19G EBUS-TBNA) in the Assessment of Mediastinal and Hilar Lymphadenopathy: a Randomised Trial
NCT number | NCT02592837 |
Other study ID # | 2015LF016B |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2016 |
Est. completion date | December 14, 2017 |
Verified date | May 2018 |
Source | Royal Brompton & Harefield NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Endobronchial ultrasound (EBUS) guided transbronchial needle aspiration (EBUS-TBNA) is an
excellent tool for sampling enlarged mediastinal and hilar lymph nodes, but only provides
needle aspirate samples which are often adequate for cytological examination only. More
advanced histopathological and immunocytopathological assessment of tissue samples, which is
particularly important in the diagnosis and staging of cancer, is often not possible with the
small cellular samples obtained by EBUS-TBNA. A new transbronchial nodal aspiration needle
(the Flex 19G EBUS-TBNA needle) has been developed with a larger needle diameter and more
flexibility at the distal end, allowing better access to some lymph nodes stations. This
needle can be passed down an EBUS scope and can hypothetically circumvent the deficiencies of
EBUS-TBNA highlighted above by providing tissue adequate for histological assessment rather
than cytological assessment alone.
This study aims to establish whether the use of the Flex 19G EBUS-TBNA needle can improve the
diagnostic yield of EBUS sampling procedures compared to the use of the conventional TBNA
needle, thereby allowing more accurate diagnoses and reducing the need repeat procedures or
more invasive surgical biopsies, without causing an increase in complication rates. Patients
with enlarged mediastinal and hilar lymph nodes referred for EBUS-TBNA will be randomised to
have their nodes sampled by either the EBUS-TBNA needle (conventional procedure) or the novel
Flex 19G EBUS-TBNA needle. The investigators hope to recruit 250 patients over a 24 month
period.
Status | Completed |
Enrollment | 250 |
Est. completion date | December 14, 2017 |
Est. primary completion date | November 14, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Scheduled for EBUS-TBNA as part of clinical care - Lymph nodes larger than 10mm in diameter - Age > 18 years - Written informed consent Exclusion Criteria: - Contraindication to needle biopsy (e.g. coagulopathy, anticoagulation, thrombocytopenia) - Inability to obtain informed consent |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Brompton Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Royal Brompton & Harefield NHS Foundation Trust | Olympus Corporation |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The difference in quality of diagnostic tissue obtained between the two study arms following 4 separate needle punctures per lymph node | Both specimens (cell pellet and tissue fragments) will be assessed by means of a semiquantitative assessment of material (normal lymph node or lesional tissue) present using the formal scoring system described by Mair. | 1 week | |
Secondary | The difference between the two study arms in the percentage of lymph nodes sampled where enough tissue is obtained for complete immunohistochemical and genetic mutation analysis. | 1 week | ||
Secondary | The difference in complication rates between the two study arms | 1 month | ||
Secondary | The difference between the two study arms in yield (quantity of diagnostic material) in patients ultimately diagnosed with sarcoidosis | 1 week | ||
Secondary | The difference between the two study arms in yield (quantity of diagnostic material) in patients ultimately diagnosed with lymphoma | 1 week | ||
Secondary | The difference in sensitivity for detecting sarcoidosis between the two study arms | Sensitivity = True Positives/(True Positives + False Negatives) | 1 week | |
Secondary | The difference in sensitivity for detecting lymphoma between the two study arms | Sensitivity = True Positives/(True Positives + False Negatives) | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|